GUGLIELMELLI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.354
EU - Europa 10.281
AS - Asia 1.181
AF - Africa 15
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
Totale 23.845
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.317
PL - Polonia 6.050
IT - Italia 1.128
IE - Irlanda 1.056
SE - Svezia 789
HK - Hong Kong 426
CN - Cina 360
CH - Svizzera 272
DE - Germania 257
FI - Finlandia 160
GB - Regno Unito 149
UA - Ucraina 146
VN - Vietnam 104
RU - Federazione Russa 103
JO - Giordania 93
SG - Singapore 70
FR - Francia 63
TR - Turchia 42
CA - Canada 37
ES - Italia 34
IN - India 34
BE - Belgio 24
TW - Taiwan 23
AT - Austria 20
AE - Emirati Arabi Uniti 11
NL - Olanda 8
RO - Romania 7
AU - Australia 6
JP - Giappone 6
BG - Bulgaria 5
SC - Seychelles 5
EU - Europa 3
KR - Corea 3
MU - Mauritius 3
BR - Brasile 2
BY - Bielorussia 2
DK - Danimarca 2
IR - Iran 2
KE - Kenya 2
NZ - Nuova Zelanda 2
ZA - Sudafrica 2
AO - Angola 1
AZ - Azerbaigian 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
GR - Grecia 1
LT - Lituania 1
MY - Malesia 1
NO - Norvegia 1
PH - Filippine 1
SD - Sudan 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 23.845
Salva come PNG Salva come JPEG
Città #
Warsaw 6.046
Fairfield 2.220
Ashburn 1.105
Woodbridge 1.062
Dublin 1.054
Seattle 950
Chandler 947
Cambridge 865
Houston 814
Wilmington 754
Ann Arbor 411
Altamura 404
Lawrence 396
Princeton 295
Bern 271
Jacksonville 255
Beijing 231
Boston 205
Florence 199
Hong Kong 199
Buffalo 135
San Diego 115
Bremen 114
Medford 103
Boardman 102
Moscow 94
Dong Ket 90
New York 86
Shanghai 45
Phoenix 41
Hillsboro 38
Izmir 37
Norwalk 33
Falls Church 30
Dearborn 28
Rome 28
Barcelona 27
London 26
Pune 25
Brussels 24
Toronto 24
Andover 23
Los Angeles 23
West Jordan 23
Salerno 20
Vienna 20
Taipei 14
Fiesole 13
Redwood City 12
Abu Dhabi 11
Milan 10
Auburn Hills 9
Hefei 9
Sesto Fiorentino 9
Washington 9
Fuzhou 8
Old Bridge 8
Singapore 8
Acton 7
Hangzhou 7
Nanjing 7
Cagliari 6
Laurel 6
Napoli 6
Pian di Scò 6
Prato 6
Redmond 6
Romainville 6
Siena 6
Castelliri 5
Fontebuona 5
Guangzhou 5
Kilburn 5
Montreal 5
Pisa 5
Sofia 5
Sydney 5
Bari 4
Brugherio 4
Cantagallo 4
Cortona 4
Frankfurt Am Main 4
Kunming 4
Monteroni D'arbia 4
Padova 4
Paris 4
Red Deer 4
Wuhan 4
Zhengzhou 4
Arezzo 3
Augusta 3
Basauri 3
Blaine 3
Bologna 3
Brescia 3
Catania 3
Chengdu 3
Chicago 3
Chiswick 3
Faenza 3
Totale 20.347
Salva come PNG Salva come JPEG
Nome #
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 266
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 255
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 245
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 244
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 240
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 240
Advances in understanding and management of myeloproliferative neoplasms 239
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 235
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 232
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 231
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives 230
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 230
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 230
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 228
EZH2 mutational status predicts poor survival in myelofibrosis. 224
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. 222
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 222
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 222
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 221
Effect of mutation order on myeloproliferative neoplasms 216
Correlazioni tra genotipo e fenotipo nelle sindromi mieloproliferative croniche Ph-negative 215
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis 215
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 214
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 212
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells 210
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 209
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium 209
Chronic myeloproliferative neoplasms: a collaborative approach. 206
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 205
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms 205
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). 204
Cardiovascular events and intensity of treatment in polycythemia vera. 204
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 204
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 203
Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms. 202
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. 201
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 200
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 193
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 185
FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis. 181
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis. 180
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis 179
Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells 174
JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone 164
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 148
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 147
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 147
MPN Score 144
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 140
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 134
miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6 129
STAT1 activation in association with JAK2 exon 12 mutations 121
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 120
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 114
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 113
Circ RNAs are here to stay: A perspective on the MLL recombinome 113
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 113
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 112
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 110
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 110
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 109
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 109
Mutations and prognosis in primary myelofibrosis. 105
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 105
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 104
Leukocytosis and risk stratification assessment in essential thrombocythemia. 102
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. 102
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 102
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion 102
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 101
Insights into JAK2-V617F mutation in CML. 99
Advances in understanding and management of polycythemia vera. 98
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 97
Treatment options for essential thrombocythemia and polycythemia vera 97
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data 97
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 97
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 97
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 97
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 97
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 96
Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis 96
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 96
Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. 95
A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS 94
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. 94
Thrombosis in primary myelofibrosis: incidence and risk factors. 91
PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. 91
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients 91
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. 90
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 90
A life-threatening ruxolitinib discontinuation syndrome 90
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. 89
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera 88
Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis 88
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 86
MIPSS701 version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis 86
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 85
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease 85
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 84
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients 84
Totale 15.267
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.442 0 0 0 0 0 0 0 0 0 0 798 644
2019/20206.348 385 436 154 548 775 756 731 814 668 421 552 108
2020/20213.515 309 361 171 539 200 304 146 271 319 448 227 220
2021/20221.881 43 162 202 47 58 73 67 195 127 74 311 522
2022/20235.085 459 1.054 252 398 330 820 618 251 391 52 141 319
2023/20241.784 86 181 323 107 185 288 55 370 41 148 0 0
Totale 24.376